The price of the targeted drug Capmatinib

Capmatinib, also known as INC280, is an oral treatment that belongs to a class of drugs called tyrosine kinase inhibitors (TKIs). It is used to treat patients with non-small cell lung cancer (NSCLC) who have certain mutations.

Capmatinib is mainly used for patients with advanced NSCLC who have METexon14 skipping mutations. This mutation causes abnormal activation of the MET tyrosine kinase, which promotes the growth and spread of cancer cells. Capmatinib blocks this growth signaling pathway by inhibiting the activity of MET kinase, thereby slowing or inhibiting the proliferation of cancer cells.

Clinical trials have shown that capmatinib has a certain degree of therapeutic effect on patients with METexon14 skipping mutationsNSCLC and has been approved by relevant regulatory agencies for the treatment of this specific type of lung cancer.

However, it is important to note that medical information is constantly being updated and new research and treatment options may be available. If you or someone you know needs information about a specific drug or treatment regimen, please consult a professional health care provider.

Capmatinib is not currently on the market in China, so patients cannot purchase it domestically. Capmatinib abroad is divided into original drugs and generic drugs. The original drug is mainly the original drug of Novartis, with a price of about 35,000 yuan and a specification of 200mg*60; the price of generic drugs is very cheap, mainly Laos generic drugs, with a price of about three to four thousand yuan. And the ingredients of original drugs and generic drugs are basically the same.